1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Discovery and Unknown stages are 2, 5, 5, 1, 1 and 1 respectively.
Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Heterozygous familial hypercholesterolemia (heFH) - Overview
- Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development
- Akeso Inc
- Amgen Inc
- Beijing Mabworks Biotech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Epicrispr Biotechnologies Inc
- Esperion Therapeutics Inc
- Innovent Biologics Inc
- LIB Therapeutics LLC
- NeuroBo Pharmaceuticals Inc
- NewAmsterdam Pharma BV
- Novartis AG
- Regeneron Pharmaceuticals Inc
- Shanghai Junshi Bioscience Co Ltd
- Verve Therapeutics Inc
- Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles
- alirocumab - Drug Profile
- Product Description
- Mechanism Of Action
- bempedoic acid - Drug Profile
- Product Description
- Mechanism Of Action
- ebronucimab - Drug Profile
- Product Description
- Mechanism Of Action
- EPIC-221 - Drug Profile
- Product Description
- Mechanism Of Action
- evinacumab - Drug Profile
- Product Description
- Mechanism Of Action
- evolocumab - Drug Profile
- Product Description
- Mechanism Of Action
- gemcabene - Drug Profile
- Product Description
- Mechanism Of Action
- inclisiran - Drug Profile
- Product Description
- Mechanism Of Action
- lerodalcibep - Drug Profile
- Product Description
- Mechanism Of Action
- MIL-86 - Drug Profile
- Product Description
- Mechanism Of Action
- obicetrapib - Drug Profile
- Product Description
- Mechanism Of Action
- ongericimab - Drug Profile
- Product Description
- Mechanism Of Action
- ST-103 - Drug Profile
- Product Description
- Mechanism Of Action
- tafolecimab - Drug Profile
- Product Description
- Mechanism Of Action
- VERVE-101 - Drug Profile
- Product Description
- Mechanism Of Action
- Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects
- Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products
- Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia
- Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years
- Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022
- Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To 8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations
- Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia
- Jul 12, 2022: Verve Therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
- May 09, 2022: Verve Therapeutics reports additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery data in non-human primates at TIDES USA 2022
- May 02, 2022: Esperion announces publication of CLEAR Harmony open-label extension study data for Bempedoic Acid in the American Journal of Cardiology
- Apr 27, 2022: Amgen announces results from two open label extension studies of Repatha (evolocumab)
- Apr 03, 2022: Innovent releases results of a phase 3 clinical study of IBI306 (PCSK-9 inhibitor) in Chinese patients with heterozygous familial hypercholesterolemia at the American College of Cardiology Annual Congress 2022
- Feb 08, 2022: Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
- Oct 15, 2021: Amgen’s evolocumab receives positive CHMP opinion for the treatment of Heterozygous familial hypercholesterolemia and Familial Hypercholesterolemia
- Sep 24, 2021: FDA approves Repatha (evolocumab) in pediatric patients age 10 and older with heterozygous familial hypercholesterolemia
- Aug 12, 2021: Innovent’s antibody therapy meets primary goal in Phase III HeFH trial
- May 19, 2021: Verve Therapeutics announces Nature publication highlighting its use of base editing to potently and durably lower blood PCSK9 and LDL-C in non-human primates
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Akeso Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Amgen Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Epicrispr Biotechnologies Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by LIB Therapeutics LLC, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NeuroBo Pharmaceuticals Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NewAmsterdam Pharma BV, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Novartis AG, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Verve Therapeutics Inc, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, 2022
- Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, 2022
- Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akeso Inc
- Amgen Inc
- Beijing Mabworks Biotech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Epicrispr Biotechnologies Inc
- Esperion Therapeutics Inc
- Innovent Biologics Inc
- LIB Therapeutics LLC
- NeuroBo Pharmaceuticals Inc
- NewAmsterdam Pharma BV
- Novartis AG
- Regeneron Pharmaceuticals Inc
- Shanghai Junshi Bioscience Co Ltd
- Verve Therapeutics Inc
